| 词条 | EVT-103 |
| 释义 |
| Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = | image = | width = | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = By mouth | class = NMDA receptor antagonist | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = | CAS_supplemental = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = | IUPHAR_ligand = | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = ENS-103 | C= | H= | N= | O= | molecular_weight = | SMILES = | StdInChI_Ref = | StdInChI = | StdInChIKey_Ref = | StdInChIKey = }}EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as an NMDA receptor subunit 2B (NR2B) antagonist.[1] As of November 2017, no recent reports of development for major depressive disorder have been identified.[1] The drug was developed as a follow-up compound to EVT-101.[2] The chemical structure of EVT-103 has not been released.[2] See also
References1. ^1 2 {{cite web|url=http://adisinsight.springer.com/drugs/800030864|title=EVT 103 - AdisInsight|website=adisinsight.springer.com}} {{Ionotropic glutamate receptor modulators}}{{Nervous-system-drug-stub}}2. ^1 {{cite journal|last1=Ruppa|first1=Kamalesh B.|last2=King|first2=Dalton|last3=Olson|first3=Richard E.|title=NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments|volume=47|year=2012|pages=89–103|issn=00657743|doi=10.1016/B978-0-12-396492-2.00007-2}} 4 : Antidepressants|Drugs with undisclosed chemical structures|Experimental drugs|NMDA receptor antagonists |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。